Add to ORKGLiraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitu
In recent years, several glucagon-like peptide-1 (GLP-1)-based therapies for the treatment of type 2...
Mahamood Edavalath1, Jeffrey W Stephens1,21Department of Diabetes and Endocrinology, Morriston Hospi...
Jonathan Pinkney1, Thomas Fox1, Lakshminarayan Ranganath21Department of Diabetes and Endocrinology, ...
Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreatic β-ce...
Type 2 diabetes mellitus (T2DM) is a progressive disease associated with significant morbidity and m...
Although advances have been achieved in the management of type 2 diabetes, current treatment options...
Glucagon-like peptide-1 (GLP-1) is an incretinhormone physiologically playing a role in glucosehomeo...
Carolyn F DeaconDepartment of Biomedical Sciences, Panum Institute, DK-2200 Copenhagen N, DenmarkAbs...
New drugs for type 2 diabetes that act on incretin metabolism have been shown to improve glycemic co...
Good glycaemic control in type 2 diabetes can be achieved by current medications, but often at the e...
New drugs for type 2 diabetes that act on incretin metabolism have been shown to improve glycemic co...
Backgrounds and Objectives Plasma proinsulin/insulin ratio which reflects b-cell dysfunction is elev...
Introduction. Liraglutide (L) is the analogue of human glucagon-like peptide 1 which stimulates gluc...
AbstractWe searched for factors influencing the clinical effects of GLP-1 analogue liraglutide in su...
Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinic...
In recent years, several glucagon-like peptide-1 (GLP-1)-based therapies for the treatment of type 2...
Mahamood Edavalath1, Jeffrey W Stephens1,21Department of Diabetes and Endocrinology, Morriston Hospi...
Jonathan Pinkney1, Thomas Fox1, Lakshminarayan Ranganath21Department of Diabetes and Endocrinology, ...
Aims. Glucagon-like peptide-1 (GLP-1) analog promotes insulin secretion by acting on pancreatic β-ce...
Type 2 diabetes mellitus (T2DM) is a progressive disease associated with significant morbidity and m...
Although advances have been achieved in the management of type 2 diabetes, current treatment options...
Glucagon-like peptide-1 (GLP-1) is an incretinhormone physiologically playing a role in glucosehomeo...
Carolyn F DeaconDepartment of Biomedical Sciences, Panum Institute, DK-2200 Copenhagen N, DenmarkAbs...
New drugs for type 2 diabetes that act on incretin metabolism have been shown to improve glycemic co...
Good glycaemic control in type 2 diabetes can be achieved by current medications, but often at the e...
New drugs for type 2 diabetes that act on incretin metabolism have been shown to improve glycemic co...
Backgrounds and Objectives Plasma proinsulin/insulin ratio which reflects b-cell dysfunction is elev...
Introduction. Liraglutide (L) is the analogue of human glucagon-like peptide 1 which stimulates gluc...
AbstractWe searched for factors influencing the clinical effects of GLP-1 analogue liraglutide in su...
Liraglutide is the first once-daily human glucagon-like peptide-1 analog available for use in clinic...
In recent years, several glucagon-like peptide-1 (GLP-1)-based therapies for the treatment of type 2...
Mahamood Edavalath1, Jeffrey W Stephens1,21Department of Diabetes and Endocrinology, Morriston Hospi...
Jonathan Pinkney1, Thomas Fox1, Lakshminarayan Ranganath21Department of Diabetes and Endocrinology, ...